ライフサイエンスコーパス: drug reaction

1 se remission or the occurrence of an adverse drug reaction.

2 ing a rare, potentially fatal, T-cell-driven drug reaction.

3 ory or poor risk assessment of recurrence of drug reaction.

4 o the pathophysiology of this severe adverse drug reaction.

5 f hepatocytes, consistent with a cholestatic drug reaction.

6 ils of 10 and 3 reports of suspected adverse drug reactions.

7 e from the eruptions usually associated with drug reactions.

8 g metabolism and have been linked to adverse drug reactions.

9 istance to pathogens and the risk of adverse drug reactions.

10 ne interindividual susceptibility to adverse drug reactions.

11 acotherapy whereas others experience adverse drug reactions.

12 that may underlie susceptibility to adverse drug reactions.

13 metabolites may be involved in idiosyncratic drug reactions.

14 nalysis linking chemical features to adverse drug reactions.

15 bited by variable drug responses and adverse drug reactions.

16 ding compounds is essential to avoid adverse drug reactions.

17 acokinetics, treatment efficacy, and adverse drug reactions.

18 a common target of inflammation and adverse drug reactions.

19 nd reduce the number and severity of adverse drug reactions.

20 and hospital nurses in reporting of adverse drug reactions.

21 distinguish from cytomegalovirus disease or drug reactions.

22 involved in other serious cutaneous adverse drug reactions.

23 annot account for most idiosyncratic adverse drug reactions.

24 histologic changes commonly associated with drug reactions.

25 information on the risks of serious adverse drug reactions.

26 levels, CD4+ lymphocyte counts, and adverse drug reactions.

27 ased screening assays for testing individual drug reactions.

28 ose existing drugs and identify rare adverse drug reactions.

29 r both predictable ADRs and hypersensitivity drug reactions.

30 ns most commonly involved in serious adverse drug reactions.

31 r serious drug-drug interactions and adverse drug reactions.

32 ce system was put in place to detect adverse drug reactions.

33 considering the increased tremor and adverse drug reactions.

34 erapy without increasing the risk of adverse drug reactions.

35 variates that influenced the rate of adverse drug reactions.

36 nor, and potentially iatrogenic; and adverse drug reactions.

37 t specific HLA alleles influence the risk of drug reactions.

38 rine disrupting chemicals (EDCs) and adverse drug reactions.

39 tudies advanced the understanding of adverse drug reactions.

40 or additional drug therapy (31%) and adverse drug reactions (18%) being the most common problems iden

41 We recorded no serious adverse drug reactions; 28 adverse events, most commonly nausea,

42 HF (11 paracetamol overdose, 2 idiosyncratic drug reaction, 3 Wilson's disease) were available.

43 without any increase in incidence of adverse drug reactions (4% vs 3%; P = .4).

44 % for ST-Cefaz) and highest rates of adverse drug reactions (5.2% vs 4.6% for Hx-Cefaz and 4.7% for S

45 Ritonavir was associated with adverse drug reactions about twice as frequently as indinavir or

46 ng to clinical efficacy, inefficacy, adverse drug reaction (ADR), and other medical causes.

47 Adverse drug reactions (ADRs) accounted for the majority of drug

48 Two spontaneously reported serious adverse drug reactions (ADRs) and 32 spontaneously reported nons

49 es identifying HLA associations with adverse drug reactions (ADRs) and one for the examination of inf

50 Adverse drug reactions (ADRs) are a central consideration during

51 Adverse drug reactions (ADRs) are a relatively common cause of m

52 Immune-mediated (IM) adverse drug reactions (ADRs) are an underrecognized source of p

53 Adverse drug reactions (ADRs) are commonplace and occur when a d

54 Idiosyncratic adverse drug reactions (ADRs) are one of the most common causes

55 the study was to investigate whether adverse drug reactions (ADRs) during immunotherapy with a grass

56 Adverse drug reactions (ADRs) pose critical public health issues

57 be more likely to have unrecognized adverse drug reactions (ADRs) than established drugs, but no rec

58 neous reports do not reliably detect adverse drug reactions (ADRs) that occur widely separated in tim

59 t carbamazepine 1 is associated with adverse drug reactions (ADRs), including hepatotoxicity; oxidati

60 of 14% of patients experienced minor adverse drug reactions (ADRs), of which 2 cases demonstrated fla

61 e classified by the investigators as adverse drug reactions (ADRs).

62 ephalosporin or incidence of serious adverse drug reactions (ADRs).

63 thiopurine therapy because of severe adverse drug reactions (ADRs); leukopenia is one of the most ser

64 fy key terms, such as adverse event, adverse drug reaction, adverse drug event, medication error, and

65 s DILI cases reported to the Swedish Adverse Drug Reactions Advisory Committee (1970-2004) for any si

66 patient susceptibility to developing adverse drug reactions, although the underlying mechanism is not

67 anism of undesirable drug effects or adverse drug reactions among those compounds, we examined their

68 ge) between the identification of an adverse drug reaction and the subsequent onset of drug-induced i

69 Thiopurine-related adverse drug reactions and thiopurine failure are frequent.

70 toms mimicking more common, entities such as drug reactions and viral syndromes.

71 he liver adapts to fasting, adverse diabetes drug reactions, and cancer.

72 used to assess treatment completion, adverse drug reactions, and factors associated with treatment di

73 uous drugs, polypharmacology-related adverse drug reactions, and multi-drug therapies, especially can

74 Xerosis, drug reactions, and neuropathy should be considered when

75 Adverse drug reactions are a frequent culprit.

76 Adverse drug reactions are a significant cause of morbidity and

77 Adverse drug reactions are a significant public health problem t

78 tionally, contact dermatitis, urticaria, and drug reactions are addressed in this review.

79 Although many adverse drug reactions are considered nonpreventable, recent dev

80 Schemes for spontaneous reporting of adverse drug reactions are important to post-marketing safety su

81 Incidents of adverse cardiac drug reactions are more common in patients with preexist

82 Idiosyncratic adverse drug reactions are unpredictable, dose-independent and p

83 ach to trimethoprim-sulfamethoxazole adverse drug reaction assessment and rechallenge to optimize pro

84 Three adverse drug reaction assessment instruments were used to determ

85 e was to determine the prevalence of adverse drug reactions associated with off-label use and evaluat

86 ating that doctors should report all adverse drug reactions associated with them to the Committee on

87 ypes can range from life-threatening adverse drugs reactions at one end of the spectrum to equally se

88 te adenovirus infections or systemic adverse drug reactions, but levels in patients with KD were not

89 studied in other types of cutaneous adverse drug reactions (cADRs).

90 Rarely a drug reaction can affect both organs concurrently.

91 s that increase the risk of life-threatening drug reactions can be clinically silent before drug expo

92 ed thrombocytopenia, a prothrombotic adverse drug reaction caused by immunoglobulin G directed agains

93 rmal necrolysis are severe adverse cutaneous drug reactions characterized by widespread skin and muco

94 Baseline and nonsteroidal anti-inflammatory drug reaction clinical data were correlated with cell ch

95 d evidence of a systemic or life-threatening drug reaction, developed a systemic drug eruption, or ha

96 and the number of harmful and severe adverse drug reactions did not differ for medications used for F

97 Although adverse drug reactions do not occur more frequently with off-lab

98 had 48 trimethoprim-sulfamethoxazole adverse drug reactions documented either at baseline or during t

99 Tremor rates and adverse drug reactions favoured the placebo group.

100 ence for a genetic predisposition to adverse drug reactions, focusing on gene variants producing alte

101 The number of adverse drug reactions for medications administered and the numb

102 dications that are associated with lichenoid drug reactions; four patients were postmenopausal; and a

103 graphics, costs, outcomes (including adverse drug reactions, functional status, ventilator time in ho

104 Patients with cutaneous drug-reaction had higher proportion of eosinophilia duri

105 Hypersensitivity drug reactions (HDRs) represent a large and important he

106 ommon medicines involved in hypersensitivity drug reactions (HDRs) to NSAIDs, no patient series studi

107 telets, leading to the prothrombotic adverse drug reaction heparin-induced thrombocytopenia (HIT).

108 e associated with an immune-mediated adverse drug reaction, heparin-induced thrombocytopenia.

109 nto the molecular mechanisms of this adverse drug reaction in adult patients with germ cell testicula

110 7; P = .0001), with no recurrence of adverse drug reactions in 74%.

111 a risk factor for the development of adverse drug reactions in an adult ICU population.

112 a novel method to better investigate adverse drug reactions in chemical space.

113 Adverse drug reactions in children are an important public healt

114 sting does not predict some forms of adverse drug reactions in humans.

115 nce techniques to reduce the risk of adverse drug reactions in patients receiving warfarin.

116 ated to calculate incidence rates of adverse drug reactions in the community from spontaneous reports

117 group) or amiodarone side effects or adverse drug reactions (in the rhythm-control group).

118 orter genes previously implicated in adverse drug reactions including simvastatin-induced myopathy an

119 Adverse drug reactions, including severe patient bleeding, may o

120 It was found that the rate of adverse drug reactions increases by 8% for every one additional

121 Differential diagnosis includes drug reactions, infections, graft-versus-host disease (G

122 idermal necrolysis (TEN) is a severe adverse drug reaction involving extensive keratinocyte death in

123 nintended 'off-targets' that predict adverse drug reactions is daunting by empirical methods alone.

124 nintended 'off-targets' that predict adverse drug reactions, is a daunting task by experimental appro

125 ed cardiotoxicity (ACT) is a serious adverse drug reaction limiting anthracycline use and causing sub

126 enal transplant recipients, reported adverse drug reactions may limit use and increase reliance on co

127 anation for HLA-linked idiosyncratic adverse drug reactions, namely that drugs can alter the repertoi

128 a given drug, creating a drug-target-adverse drug reaction network.

129 is/granulocytopenia (CIAG), a severe adverse drug reaction occurring in up to 1% of treated individua

130 induced thrombocytopenia (HIT) is an adverse drug reaction occurring in up to 5% of patients exposed

131 is a relatively common prothrombotic adverse drug reaction of unusual pathogenesis that features plat

132 By integrating data sources about adverse drug reactions of drugs with an established cheminformat

133 tevens-Johnson syndrome are severe cutaneous drug reactions of unknown mechanism.

134 nduced taste disturbance is a common adverse drug reaction often triggered by drug secretion into sal

135 These events might be responsible for drug reactions or development of certain diseases.

136 Secondary outcomes included adverse drug reaction, PICC line complication, and a composite o

137 uisition cost, and costs of treating adverse drug reactions probably or possibly related to study dru

138 Three subjects reported mild adverse drug reactions related to FCM; two of these were conside

139 Our institutional adverse drug reaction reporting program was used to identify any

140 When drug reactions resembling allergy occur, they are called

141 d to determine the probability of an adverse drug reaction resulting from drug therapy.

142 ons during hypothermia and increased adverse drug reaction risk complicates concurrent pharmacotherap

143 s with the strongest associations to adverse drug reaction risk in the intensive care unit are presen

144 more frequently with off-label use, adverse drug reaction risk increases with each additional off-la

145 quently discovered to have suspected adverse drug reactions (SADRs).

146 Adverse drug reaction screens in a kidney panel revealed no off-

147 e identified clinically significant systemic drug reactions (SDR) and evaluated risk factors in patie

148 cent advances in pharmacogenetics of adverse drug reactions show promise, the small size of the popul

149 literature documenting the risk for adverse drug reactions specific to bleeding and/or clotting with

150 We included 18 of 333 adverse drug reaction studies and 22 of 61 variant allele review

151 n of the role that genetics plays in adverse drug reactions that are either predictable extensions of

152 ve of pharmacovigilance is to detect adverse drug reactions that are unknown or novel in terms of the

153 reactions are common clinical acute adverse drug reactions that can exacerbate a patient's condition

154 ole of the adaptive immune system in adverse drug reactions that target the liver has not been define

155 th Organization's classification for adverse drug reactions, the association between bortezomib use a

156 In an effort to prevent adverse drug reactions, the FDA mandates the evaluation of the p

157 ssed daily for the development of an adverse drug reaction through active surveillance.

158 thy should be recognized as an idiosyncratic drug reaction to many NSAIDS.

159 s any clinical event described as an adverse drug reaction to one or more drugs.

160 lly lethal, immunologically mediated adverse drug reaction to unfractionated heparin or, less commonl

161 cholesterol levels that could cause adverse drug reactions to cholesterol-lowering drugs such as sta

162 that may be associated with the rare adverse drug reaction torsades de pointes.

163 Severity and harm of the adverse drug reaction were also assessed.

164 Rates of adverse drug reaction were low (<4% in both groups) but slightly

165 One hundred and sixteen adverse drug reactions were categorized dichotomously (Food and

166 The incidence and severity of other adverse drug reactions were comparable between the 2 groups.

167 Adverse drug reactions were less common in the TMP-SMX plus plac

168 Discontinuations due to adverse drug reactions were lowest for TDF+FTC+RAL (1.9%; 95% CI

169 The most common adverse drug reactions were ocular side effects, including hyper

170 tions was 3.2% in the intravenous group, and drug reactions were rare in both groups (intravenous: 0.

171 Three adverse drug reactions were regarded as both serious and unexpec

172 Adverse drug reactions were reported by 1174 (35.7%) patients, o

173 ) of 51 events classified as serious adverse drug reactions were reported.

174 but no suspected unexpected serious adverse drug reactions were seen.

175 occus aureus sinusitis, and multiple adverse drug reactions whose T cells were unable to produce IFN-

176 enetic variants associated with this adverse drug reaction will further our mechanistic understanding

177 es virus (HHV) reactivation is well known in drug reaction with eosinophilia and systemic symptom (DR

178 vens-Johnson Syndrome (SJS), and 11 cases of Drug Reaction with Eosinophilia and Systemic Symptoms (D

179 uses (HHVs) contribute to the development of drug reaction with eosinophilia and systemic symptoms (D

180 added significantly to our understanding of drug reaction with eosinophilia and systemic symptoms (D

181 Drug reaction with eosinophilia and systemic symptoms (D

182 ersensitivity syndrome (DIHS), also known as drug reaction with eosinophilia and systemic symptoms (D

183 is a major mechanism in the pathogenesis of drug reaction with eosinophilia and systemic symptoms (D

184 Drug reaction with eosinophilia and systemic symptoms (D

185 ar to the more severe eczema vaccinatum, and drug reaction with eosinophilia and systemic symptoms sy

186 DRs, such as drug hypersensitivity syndrome, drug reaction with eosinophilia and systemic symptoms sy

187 Less than 1% of women reported adverse drug reactions, with no increase in HIV-positive women o